Finance entity
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention AbbVie, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline.
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention AbbVie, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline. At 6, the average consequence score sits above the same-window beat average of 5.8. We currently track 1 Finance story that mention Brad Pagano, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 174 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Brad Pagano. Shared-story counts are live from our verified record — not editorial picks.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Brad Pagano is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
